Forever Chemicals, Finite Defenses: PFAS Burden the Liver, Break Mitochondria, and Outpace Modern Regulation
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27062723 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Aarush Goyal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Health, Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, A…. Hauptthemen laut MEDLINE: Liver, Fluorocarbons, Mitochondria, Environmental Pollutants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH NIGMS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Per- and polyfluoroalkyl substances (PFAS) continue to be one of the most persistent global contaminants and are increasingly recognized as leading metabolic- and hepatic-dysfunction mediators. Despite extensive investigation of PFAS toxicity, a critical gap in the identification and integration of toxicokinetic drivers of hepatic bioaccumulation with mechanistic pathways driving mitochondrial and nuclear receptor-related injury, more specifically, with respect to alternative PFAS strategies, still remains. Legacy PFAS, including PFOA and PFOS, accumulate in the liver and disturb mitochondrial homeostasis as they disrupt β-oxidation, induce oxidative stress, and alter lipid and bile acid metabolism. Meanwhile, the next-generation PFAS variants (including short-chain and polymeric substitutes) are rapidly increasing in environmental concentrations, but remain insufficiently characterized and poorly regulated, raising concerns that substitution-based strategies may maintain their toxicological risk. We summarize the evidence of the association between PFAS bioaccumulation and mitochondrial dysfunction, metabolic reprogramming, and inflammatory signaling, and illustrate mechanistic convergence across legacy and emerging PFAS. We also review insights from recent experimental models, such as 3D hepatocyte systems and human-relevant receptor platforms that more closely mimic chronic exposure states. This review emphasizes mechanistic convergence across legacy and emerging PFAS, highlighting shared pathways that may persist despite chemical substitution. Thus, we discuss key gaps in monitoring, toxicity assessment, and policy, including the requirement of regulatory paradigms that treat PFAS as a class rather than individual compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Radiation Health, Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
- Faculty of Pharmacy, Ataturk University, Ataturk Mah. Yakutiye, Erzurum 25240, Türkiye.
ORCID-Profile: Melike Kesmez, Nukhet Aykin-Burns
Förderung
- NIH NIGMS
- National Institute of General Medical Sciences
Zitieren
APA
Goyal, A., Kesmez, M., & Aykin-Burns, N. (2026). Forever Chemicals, Finite Defenses: PFAS Burden the Liver, Break Mitochondria, and Outpace Modern Regulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062723
Vancouver
Goyal A, Kesmez M, Aykin-Burns N. Forever Chemicals, Finite Defenses: PFAS Burden the Liver, Break Mitochondria, and Outpace Modern Regulation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062723
BibTeX
@article{Goyal2026,
author = {Goyal, Aarush and Kesmez, Melike and Aykin-Burns, Nukhet},
title = {Forever Chemicals, Finite Defenses: PFAS Burden the Liver, Break Mitochondria, and Outpace Modern Regulation},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27062723}
}
EUVIMED